US Patent

US7635704 — Stable crystal of 4-oxoquinoline compound

Method of Use · Assigned to Japan Tobacco Inc · Expires 2026-10-26 · 0y remaining

Vulnerability score 63/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a stabilized crystal of a specific compound used in the drug Tybost.

USPTO Abstract

Provision of a stabilized crystal of 6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-methoxy-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (compound A). A crystal of compound A, which shows a particular X-ray powder diffraction pattern of a characteristic diffraction peaks at diffraction angles 2θ(°) as measured by X-ray powder diffractmetry.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-257 — Tybost
U-257 — Vitekta
U-257 — Vitekta
U-257 — Tybost

Patent Metadata

Patent number
US7635704
Jurisdiction
US
Classification
Method of Use
Expires
2026-10-26
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Japan Tobacco Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.